{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "LOINC|ACTIVE|CHEM|Body fld" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03935984: Phase 4 Interventional Recruiting Primary Hyperparathyroidism
(2019)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03938935: Not Applicable Interventional Unknown status Flexor Tendon Repair
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03673657: Phase 2 Interventional Completed Local Advanced Non-small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00146432: Phase 2/Phase 3 Interventional Completed Septicemia
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04426201: Phase 2 Interventional Terminated COVID-19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01309425: Phase 1 Interventional Completed Healthy Volunteer
(2011)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
EU-Orphan Drug:EU/3/03/138
Source URL:
Class:
PROTEIN
Status:
First approved in 1955
Class:
PROTEIN
